The cost-effectiveness of orphan drugs.
Weinstein
M C
MC
D003362:Cost-Benefit Analysis; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy* / Q000191:economics / Q000209:etiology; D009965:Orphan Drug Production / Q000191:economics*; D014481:United States; D026712:Value of Life; D000515:alpha 1-Antitrypsin / Q000627:therapeutic use; D019896:alpha 1-Antitrypsin Deficiency
D000515:alpha 1-Antitrypsin